On July 31, Sanofi announced 2025H1 Performance, Total Revenue in the First Half of the Year: 198.89Billion euros (approximately 218.00Billion USD, according to2025Converted at the annual average exchange rate,1Euro=1.0961USD, same below), increasing by 9.9% year-on-year%(Calculated at a fixed exchange rate, the same below); R&D investment of 37.17100 million euros (approximately 40.74Billion US dollars), accounting for 18.7% of total revenue%。In terms of regional distribution, the U.S. market revenue was 95.35.100 million euros (approximately 104.51Billion US dollars,+16.4%), Europe market revenue 41.44Billion euros (approximately 45.42"Billion US dollars,"+1.8%), Revenue in China Market 13.8815.21 billion euros (approximately 15.21Billion USD, +0.1%）。
In terms of business segments, Sanofi's six major segments—immunology, rare diseases, neurology, oncology, vaccines, and others—generated revenues of 75.57 respectively.Billion euros (approximately 82.83Billion USD), 31.08Billion euros (approximately 34.07billion US dollars), 1.38100 million euros (approximately 1.51Billion US dollars), 5.05Billion euros (approximately 5.54Billion USD), 25.40EUR billion (approximately 27.84Billion USD) and 60.41100 million euros (approximately 66.22(Billion USD).
InImmunology Field, Sanofi'sBlockbuster product Dupixent (Dupilumab) is gaining strong momentum,The first six months saw sales of 7.312 billion euros (approximately 8.015 billion US dollars)Billion USD, +20.7%）。The inflammatory landscape of Dupilumab continues to expand.In May this year inThe United States Reports New Cases of Chronic Spontaneous Urticaria (CSU), andJune becomesThe First Targeted Therapy for Bullous Pemphigoid (BP). It is worth mentioning that,Dupilumab faces its first strong competitor in the COPD field this year, as GSK's Mepolizumab (Nucala) expanded its target population in May to include COPD patients with eosinophil levels ≥150 cells/μL. The competition is intensifying, with Roche and Amgen’s jointly developed IL-33R antibody.Astegolimab Achieves One Win and One Loss in Two Studies. A similar plotline occurred with Sanofi's IL-33 monoclonal antibody.Itepekimab in Action。
InVaccine Field, Respiratory syncytial virus (RSV) neutralizing antibody Nirsevimab (Beyfortus) is becomingSanofi's PillarProduct. This product is the first neutralizing antibody for infants and young children in the RSV field, and its commercial performance has been good since it was launched.Last year hasPromoted to "blockbuster".In the first half of this year,Beyfortus Sales Maintain Rapid Growth,Brought 356 million euros (approximately 390 million USD) to SanofiUSD billion, +79%) in revenue, with the portion reported by AstraZeneca amounting to USD 628 million.The first competitor of this product has officially debuted: the neutralizing antibody developed by Merck.Enflonsia（Clesrovimab was approved for marketing by the FDA in June this year.。
InRare Disease Field, Sanofi has built a rich product portfolio and has launched Altuviiio (efanesoctocog alfa）、Nexviazyme（Avalglucosidase alfa）、Xenpozyme（olipudase alfa) and 12 other products. Among them, the hemophilia drug Altuviiio rapidly penetrated the market within two years of its launch, with sales in the first half of this year reaching 542 million euros (approximately 594 million US dollars, +95.4%), placing it on the verge of becoming a "blockbuster" drug. In the field of hemophilia, another key product from Sanofi...Qfitlia (fitusiran) has been approved for marketing in March this year., becoming the first RNAi therapy in this field, generating $1 million in revenue within three months of its launch.Neurology andOncology FieldCharging up.Aubagio（Teriflunomide) has long passed its prime, new bloodtolebrutinibIs about to take over, itsExpected to become the first BTK inhibitor in the multiple sclerosis field in September this year.CD38 Antibody Sarclisa (Isatuximab) It has covered the first-line, second-line, and third-line treatments for multiple myeloma so far, and can be used for newly diagnosed multiple myeloma patients suitable for autologous stem cell transplantation, andDarzalex（Daratumumab) United Front。In the first half of the year,SarclisaMaintaining steady growth, with revenue of 276 million euros (approximately 303 million USD)Billion USD, +22.5%).Fully complete the consumer health business (Opella) After the split, Sanofi began to strengthen its efforts in BD deals, having completed 9 project transactions and 3 acquisition deals within 7 months, including$9.5 Billion Acquisition of Blueprint MedicinesLarge transactions.Looking ahead to 2025 performance, Sanofi expects revenue growth rate in the high single digits.Copyright © 2025 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
